Publications
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Primary testicular lymphoma2017 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Practical approach to management of chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone2016 | Faculty of Medicine in Hradec Králové
- Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia2015 | Faculty of Medicine in Hradec Králové
Loading network view...
